Peptide Receptor Radionuclide Therapy

DRUG2 trials

Sponsors

Methodist Health System, Chandrikha Chandrasekhara

Conditions

Carcinoid SyndromeDiarrheaGastroenteropancreatic Neuroendocrine TumorNeuroendocrine Tumors

Phase 2

Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl

WithdrawnNCT04713202

Chandrikha ChandrasekharaCarcinoid Syndrome, Diarrhea, Neuroendocrine Tumors

Start: 2021-03-03End: 2024-02-29Updated: 2023-02-10

Unknown Phase

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

RecruitingNCT04090034

Methodist Health SystemGastroenteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors

Start: 2024-03-28End: 2026-06-28Target: 50Updated: 2026-03-20